A phase i pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors

Investigational New Drugs

Volumn 33, Issue 2, 2015, Pages 321-331

  Peethambaram, P P ^a   Hartmann, L C ^a   Jonker, D J ^c   De Jonge, M ^f   Plummer, E R ^d   Martin, L ^b   Konner, J ^e   Marshall, J ^g   Goss, G D ^c   Teslenko, V ^h   Clemens, P L ^h   Cohen, L J ^h   Ahlers, C M ^h   Alland, L ^h,i  

^a MAYO CLINIC CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d Northern Centre for Cancer Care   (United Kingdom)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g GEORGETOWN UNIVERSITY   (United States)

^h BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

ⁱ ASTRAZENECA   (United Kingdom)

Author keywords

Advanced cancer; Epothilone; Folate conjugate; Phase I trial

Indexed keywords

ANTINEOPLASTIC AGENT; BMS-753493; EPOTHILONE DERIVATIVE; FOLIC ACID;

ADULT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HALF LIFE TIME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOTHILONES; FEMALE; FOLIC ACID; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 84939941586     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0171-9     Document Type: Article

References (25)

1. Jones MB, Neuper C, Clayton A, Mariani A, Konecny G, Thomas MB, Keeney G, Hartmann L, Podratz KC (2008) Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas. Int J Cancer 123(7):1699-1703
2. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr, Old LJ, Rettig WJ (1993) Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 142(2):557-567
3. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338(2):284-293
4. Ross JF, Chaudhuri PK, Ratnam M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73(9):2432-2443
5. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC (2008) Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108(3):619-626
6. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr, Kamen BA (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52(12):3396-3401
7. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55(11):2325-2333
8. Kowalski RJ, Giannakakou P, Hamel E (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 272(4):2534-2541
9. Vlahov IR, Vite GD, Kleindl PJ, Wang Y, Santhapuram HK, You F, Howard SJ, Kim SH, Lee FF, Leamon CP (2010) Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid. Bioorg Med Chem Lett 20(15):4578-4581
10. Covello K, Flefleh C, McGlinchey C, Menard K, Wen M-L, Westhouse R, Wiebesiek A, Reddy A, Vlahov I, Hunt J, Rose W, Leamon C, Vite G, Lee FYF (2008) Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development. in AACR Annual Meeting. Los Angeles
11. BMS data on file
12. Sawada Y, Sugita K, Kabashima R, Nakamura M, Tokura Y (2009) Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratinocytes. J Eur Acad Dermatol Venereol 23(11):1333-1335
13. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P (2010) Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28(20):3256-3263
14. Ixempra package insert, revised 10/2011. http://packageinserts.bms.com/pi/pi-ixempra.pdf. Accessed June 11, 2012
15. Leamon CP, Reddy JA, Vlahov IR, Kleindl PJ, Vetzel M, Westrick E (2006) Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate. Bioconjug Chem 17(5):1226-1232
16. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, Leamon CP (2007) Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 67(9):4434-4442
17. Siegel BA, Dehdashti F, Mutch DG, Podoloff DA, Wendt R, Sutton GP, Burt RW, Ellis PR, Mathias CJ, Green MA, Gershenson DM (2003) Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 44(5):700-707
18. Lu Y, Low PS (2002) Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 51(3):153-162
19. Lu Y, Sega E, Low PS (2005) Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer 116(5):710-719
20. Amato RJ, Fagbeyiro B, Messmann R, Low PS (2005) Phase I trial of EC90 (keyhole-limpet hemocyanin fluorescein isothiocyanate conjugate) with GPI-0100 adjuvant followed by EC17 (Folate-Fluorescein Isothiocyanate Conjugate) in Patients (pts) with metastatic renal cell carcinoma (MRCC). ASCO Meet Abstr 23(16-suppl):2590
21. Messmann R, Amato R, Hernandez-McClain J, Conley B, Rogers H, Lu J, Low P, Bever S, Morgenstern D (2007) A phase II study of FolateImmune (EC90 with GP1-0100 adjuvant followed by EC17) with low dose cytokines interleukin-2 (IL-2) and interferon-{alpha} (IFN-{alpha}) in patients with refractory or metastatic cancer. ASCO Meet Abstr 25(18-suppl):13516
22. Sausville E, LoRusso P, Quinn M, Forman K, Leamon C, Morganstern D, Bever S, Messmann R (2007) A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors. ASCO Meet Abstr 25(18-suppl):2577
23. Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, Leamon CP (2006) Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 16(19):5093-5096
24. Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, LoRusso P (2009) Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 49(12):1467-1476
25. Naumann R, Symanowski J, Ghamande S (2010) Precedent: a randomized phase II trial comparing EC145 and pegylated lisosomal doxyrubicin (PLD) versus PLD alone, in patients with platinum-resistant ovarian cancer. J Clin Oncol 31(35):4400-4406